UPDATE: Frequency Therapeutics to present newest FX-322 clinical trial results on September 17, 2019 [early]

Latest FX-322 study results… earlier than expected? The upcoming presentation, “Phase 1/2 Hearing Loss Trial of Intratympanic FX322, a Progenitor Cell Activator,” was previously scheduled for September 18, 2019. But according to the AAO-HNSF Annual Meeting website, the presentation date has been changed from September 18 to September 17. Coming Sooner… Here is the updated … Continue reading UPDATE: Frequency Therapeutics to present newest FX-322 clinical trial results on September 17, 2019 [early]